Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCR Immunochemotherapy in B-Cell Prolymphocytic Leukemia
NCT00281931Phase 2Terminated
- Sponsor
- German CLL Study Group
- Start
- Sep 1999
- Primary completion
- Apr 2006
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, cyclophosphamide and fludarabine in prolymphocytic leukemia (PLL), sponsored by German CLL Study Group. Primary endpoints: Overall survival, Progression-free survival and 1 more. Started Sep 1999; status: terminated.
02
Drugs
rituximabcyclophosphamidefludarabine
03
Conditions
prolymphocytic leukemia (PLL)
Beyond the preview
Go deeper on NCT00281931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00281931.